

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau







A6

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 453/02, 453/06, 487/08, A61K 31/445, C07F 5/02		A1	(11) International Publication Number: WO 97/30998
			(43) International Publication Date: 28 August 1997 (28.08.97)
(21) International Application Number: PCT/SE97/00294			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 21 February 1997 (21.02.97)			
(30) Priority Data: 9600683-8 23 February 1996 (23.02.96) SE			
(71) Applicant (for all designated States except US): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).			
(72) Inventors; and (75) Inventors/Applicants (for US only): MACOR, John [US/US]; 95 Braeloch Crossing, Penfield, NY 14526 (US). WU, Edwin [US/US]; 147 Ashley Drive, Rochester, NY 14620 (US).			
(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).			Published <i>With international search report.</i> <i>With amended claims.</i>

(54) Title: AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY



(57) Abstract

A compound of formula (I) wherein: A is (II), (III), (IV) or (V); X is O or S; Y is O or S; G and D are independently nitrogen or carbon with the proviso that no more than one of G, D, or E is nitrogen; E is N or C-R₄; R₁ is hydrogen or methyl; R₂ is hydrogen or fluoro; R₃ is hydrogen, halogen, C₁ to C₃ alkyl, -OR₅, -CN, -CONH₂, -CO₂R₅, -NR₅R₆ or phenyl optionally substituted with one to three of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃; R₄ is hydrogen, halogen, C₁ to C₃ alkyl, -OR₅, -CN, -CONH₂, -CO₂R₅, -NR₅R₆ or phenyl optionally substituted with one to three of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃; or R₂ and R₃ or R₃ and R₄ may together represent a fused phenyl ring optionally substituted with one or two of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃; R₅ and R₆ are independently hydrogen or C₁ to C₃ alkyl; or an enantiomer thereof, and pharmaceutically acceptable salts thereof, processes for preparing them, compositions containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders, as well as intermediates and use of intermediates in synthesis.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY

Field of the Invention

- 5 This invention relates to novel azabicyclic esters of carbamic acids or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. A further object is to provide active compounds which are potent ligands for nicotinic acetylcholine receptors (nAChR's).

10 Background of the Invention

The use of compounds which bind nicotinic acetylcholine receptors in the treatment of a range of disorders involving reduced cholinergic function such as Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, neuroprotection, schizophrenia, analgesia, Tourette's syndrome, and Parkinson's disease has been discussed in "Nicotinic Acetylcholine Receptors: Molecular Biology, Chemistry, and Pharmacology", Chapter 5 in Annual Reports in Medicinal Chemistry, Volume 30, pp. 41-50, Academic Press Inc., San Diego, CA (1995) and in "Neuronal Nicotinic Acetylcholine Receptors," Drug News & Perspectives, Volume 7, pp. 205-223 (1994).

20


US Patent 5,468,875 discloses N-alkylcarbamic acid 1-azabicyclo[2.2.1]hept-3-yl esters which are centrally active muscarinic agents useful in the treatment of Alzheimer's disease and other disorders.

- 25 N-(2-Alkoxyphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl esters are disclosed in *Pharmazie*, **48**, 465-466 (1993) along with their local anaesthetic activity.

N-Phenylcarbamic acid 1-azabicyclo[2.2.2]octan-3-yl esters substituted at the *ortho* position on the phenyl ring are described as local anaesthetics in *Acta Pharm. Suecica*, **7**, 239-246
30 (1970).


Disclosure of the Invention

According to the invention we provide a compound of formula



wherein:

A is



X is O or S;

Y is O or S;

15 G and D are independently nitrogen or carbon with the proviso that no more than one of G, D, or E is nitrogen;

E is N or C-R₄;

R₁ is hydrogen or methyl;

R₂ is hydrogen or fluoro;

20 R₃ is hydrogen, halogen, C₁ to C₃ alkyl, -OR₅, -CN, -CONH₂, -CO₂R₅, -NR₅R₆ or phenyl optionally substituted with one to three of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃;

R₄ is hydrogen, halogen, C₁ to C₃ alkyl, -OR₅, -CN, -CONH₂, -CO₂R₅, -NR₅R₆ or phenyl optionally substituted with one to three of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃;

or R₂ and R₃ or R₃ and R₄ may together represent a fused phenyl ring optionally substituted with one or two of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃;

R₅ and R₆ are independently hydrogen or C₁ to C₃ alkyl;
or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

10 The compounds of formula I are potent ligands for nicotinic acetylcholine receptors.

Unless otherwise indicated, the term "C₁-C₃ alkyl" referred to herein denotes a straight or branched chain alkyl group having from 1 to 3 carbon atoms or a cyclic alkyl group having 3 carbon atoms. Examples of such groups are methyl, ethyl, n-propyl, i-propyl and
15 cyclopropyl.

Unless otherwise indicated, the term "halogen" referred to herein denotes fluoro, chloro, bromo or iodo.

20 Preferred compounds of the invention are compounds of formula I wherein A is formula II or IV; R₂ is hydrogen; X and Y are oxygen and G, D, and E are carbon.

Particularly preferred compounds of the invention include the following:

25 N-phenylcarbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(4-bromophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(4-methylphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(4-methoxyphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(3,4-dichlorophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
30 N-(4-cyanophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;

- N-phenylcarbamic acid 1-azabicyclo[2.2.1]heptan-3-yl ester;
N-(3-methoxyphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-phenylthiocarbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(2-pyridyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
5 N-(1-naphthyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-phenylcarbamic acid (3R)-1-azabicyclo[2.2.2]octan-3-yl ester;
N-phenylcarbamic acid (3S)-1-azabicyclo[2.2.2]octan-3-yl ester;
N-(4-pyridyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(m-biphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
10 N-(3-quinoliny)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester.

More particularly preferred compounds of the invention include the following:

- N-(4-bromophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
15 N-(4-methylphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(3,4-dichlorophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(m-biphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester.

Other compounds of the invention include:

- 20 N-(2-fluorophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(3-fluorophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(4-fluorophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(4-chlorophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
25 N-(3-chlorophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(3-bromophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(3-chloro-4-fluorophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(4-chloro-3-fluorophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester.


According to the invention, we further provide a process for the preparation of compounds of formula I, and enantiomers thereof and pharmaceutically acceptable salts thereof.

Methods of Preparation

The compounds of formula I may be prepared according to the methods of Scheme 1, Scheme 2, and Scheme 3. In the reaction schemes and text that follow A, X, Y, G, D, E, R₁, R₂, R₃, R₄, R₅, and R₆, unless otherwise indicated, are as defined above for formula I.

10 Method a)

Scheme 1



15

Compounds of formula I may be prepared from the condensation of a compound of the formula VI with an isocyanate or isothiocyanate of the formula VII in an inert solvent in the presence of a catalyst. Suitable inert solvents include ethers, for example, diethyl ether, tetrahydrofuran or dioxane; acetonitrile, toluene, N,N-dimethylformamide, and N-methylpyrrolidin-2-one. Preferably the solvent is acetonitrile. Suitable catalysts include tertiary amines such as trialkylamines, for example, triethylamine; 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), and 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), preferably triethylamine, or dibutyltin dilaurate. The reaction is usually conducted at a temperature from about 25 °C to about 154 °C, preferably about 25 °C to about 85 °C and


20

at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere).

Method b)

Alternatively, a compound of formula I can be prepared according to Scheme 2.

Scheme 2



10

A compound of formula I may be prepared from a compound of formula IX via removal of the borane complex in a compound of formula IX using acid in an inert solvent. Suitable acids include mineral acids, for example, hydrochloric and hydrobromic acid; preferably hydrochloric acid. Suitable inert solvents include C₁ to C₄ alcohols and acetone; preferably acetone. The reaction is usually conducted at a temperature of about -10 °C to about 50 °C, preferably at about 0 °C to about 25 °C.

Compounds of formula IX are novel and can be prepared from the condensation of a compound of the formula VIII with an isocyanate or isothiocyanate of the formula VII in an inert solvent in the presence of a catalyst. Suitable inert solvents and catalysts, and reaction conditions are the same as described under method (a) above, for the condensation of the compound of formula VI with the compound of formula VII.

20


Compounds of formula VIII, which is the borane complex of a compound of formula VI, are novel and may be prepared via the treatment of a compound of formula VI with an equimolar amount of borane in tetrahydrofuran at about -10 °C to about 25 °C, preferably at about 0 °C. Extractive work up affords a compound of formula VIII which is generally used directly in the next step of the reaction sequence.

Compounds of formula VIII may be used as starting material in condensation reactions as well as starting material in a synthesis of a ligand for nicotinic acetylcholine receptors.

10 Method c)

Alternatively, compounds of formula I can be prepared as outlined in Scheme 3.

Scheme 3



A compound of formula I may be prepared from the sequential reaction of a compound of formula XI with a carbonyl donating compound of formula XII, wherein Y is as defined above and L is a leaving group, for example, chloride or imidazole, followed by immediate reaction of the resulting mixture with a compound of formula VI all done in the presence of a basic catalyst in an inert solvent. The preferred compound of formula XII is carbonyldiimidazole. Suitable bases include trialkylamines, for example, triethylamine; 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), and 1,5-diazabicyclo[4.3.0]non-5-ene (DBN); preferably triethylamine. Suitable inert solvents include N,N-dimethylformamide,

20

acetonitrile, ethers, for example, tetrahydrofuran and dioxane, and acetone; preferably acetonitrile. The reaction is usually conducted at a temperature from about 25 °C to about 154 °C, preferably about 25 °C to about 85 °C and at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere).

5

Compounds of formulae VI, VII, XI and XII are either commercially available or may be prepared by methods known to one skilled in the art.

The compounds of the invention and intermediates may be isolated from their reaction mixtures, and, if necessary, be further purified using standard techniques.

10

Acid addition salts of the compounds of formula I which may be mentioned include salts of mineral acids, for example, the hydrochloride and hydrobromide salts; and salts formed with organic acids such as formate, acetate, maleate, benzoate and fumarate salts.

15

Acid addition salts of compounds of formula I may be formed by reacting the free base or a salt, enantiomer or protected derivative thereof, with one or more equivalents of the appropriate acid. The reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, for example, water, dioxane, ethanol, tetrahydrofuran or diethyl ether, or a mixture of solvents, which may be removed in vacuum or by freeze drying. The reaction may be a metathetical process or it may be carried out on an ion exchange resin.

20

The compounds of formula I exist in tautomeric or enantiomeric forms, all of which are included within the scope of the invention. The various optical isomers may be isolated by separation of a racemic mixture of the compounds using conventional techniques, for example, fractional crystallization or chiral HPLC. Alternatively the individual enantiomers may be made by reaction of the appropriate optically active starting materials under reaction conditions which will not cause racemization.

25

30

Intermediate compounds also exist in enantiomeric forms and may be used as purified enantiomers, racemates or mixtures.

Utility

5

The compounds of formula I are agonists of nicotinic acetylcholine receptors ["Nicotinic Acetylcholine Receptors: Molecular Biology, Chemistry, and Pharmacology", Chapter 5 in Annual Reports in Medicinal Chemistry, Volume 30, pp. 41-50, Academic Press Inc., San Diego, CA (1995)]. While not being limited by theory, it is believed that agonists of the $\alpha 7$ nAChR (nicotinic acetylcholine receptor) subtype should be useful in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders, and have advantages over compounds which are, or are also, agonists of the $\alpha 4$ nAChR subtype. Therefore, compounds which are selective for the $\alpha 7$ nAChR subtype are preferred. The compounds of the invention are indicated as pharmaceuticals, in particular in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders. Examples of psychotic disorders include schizophrenia, mania, manic depression and anxiety. Examples of intellectual impairment disorders include Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, autism and Attention Deficit Hyperactivity Disorder. The compounds of the invention may also be useful as analgesics in the treatment of pain (including chronic pain) and in the treatment or prophylaxis of Parkinson's disease, Huntington's disease, Tourette's syndrome, Amyotrophic Lateral Sclerosis and neurodegenerative disorders in which there is dysfunction of the cholinergic system. The compounds may further be indicated for the treatment or prophylaxis of jetlag, for use in inducing the cessation of smoking, and for the treatment or prophylaxis of nicotine addiction (including that resulting from exposure to products containing nicotine).

25

It is also believed that compounds of formula I may be useful in the treatment and prophylaxis of inflammatory bowel diseases, for example, ulcerative colitis.

Thus, according to a further aspect of the invention we provide a compound of formula I, or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical.

- 5 According to another aspect of the invention is the use of a compound of formula I, an enantiomer thereof or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of one of the above mentioned diseases or conditions; and a method of treatment or prophylaxis of one of the above mentioned diseases or conditions, which comprises administering a therapeutically effective amount of
10 a compound of formula I, or an enantiomer thereof or a pharmaceutically acceptable salt thereof, to a person suffering from or susceptible to such a disease or condition.

- For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However,
15 in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.1 mg to about 20 mg per kg of animal body weight, preferably given in divided doses 1 to 4 times a day or in sustained release form. For man, the total daily dose is in the range of from 5 mg to 1,400 mg, more preferably from 10 mg to 100 mg, and unit dosage forms suitable for oral administration comprise from
20 2 mg to 1,400 mg of the compound optionally admixed with a solid or liquid pharmaceutical carrier or diluent.

Pharmaceutical compositions

- 25 The compounds of formula I and enantiomers thereof and pharmaceutically acceptable salts thereof may be used on their own, or in the form of appropriate medicinal compositions. Administration may be by, but is not limited to, enteral (including oral, sublingual or rectal), intranasal, topical or parenteral routes. Conventional procedures for the selection and preparation of suitable pharmaceutical compositions are described in, for example,

"Pharmaceuticals - The Science of Dosage Form Designs", M.E. Aulton, Churchill Livingstone, 1988.

According to the invention, there is provided a pharmaceutical composition for treating or preventing a condition or disorder as exemplified above arising from dysfunction of nicotinic acetylcholine receptor neurotransmission in a mammal, preferably a human, comprising an amount of a compound of formula I, an enantiomer thereof or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and optionally an inert pharmaceutically acceptable carrier.

10

According to a further aspect of the invention, there is provided a pharmaceutical composition including preferably less than 80% by weight and more preferably less than 50% by weight of a compound of the invention optionally in admixture with an inert pharmaceutically acceptable diluent or carrier.

15

Examples of diluents and carriers are: for tablets and dragees: lactose, starch, talc, stearic acid; for capsules: tartaric acid or lactose; for injectable solutions: water, alcohols, glycerin, vegetable oils; for suppositories: natural or hardened oils or waxes.

Compositions in a form suitable for oral, i.e. oesophageal, administration include tablets, capsules, syrups and dragees; sustained release compositions include those in which the active ingredient is bound to an ion exchange resin which is optionally coated with a diffusion barrier to modify the release properties of the resin.

There is also provided a process for the preparation of such a pharmaceutical composition which comprises mixing the ingredients.

Pharmacology

The pharmacological activity of the compounds of the invention may be measured in the tests set out below:

5

Test A - Assay for affinity to the $\alpha 7$ nAChR subtype

[¹²⁵I]- α -Bungarotoxin (BTX) binding to rat hippocampal membranes.

Rat hippocampi were homogenized in 20 volumes of cold homogenization buffer (HB: concentrations of constituents (mM): tris(hydroxymethyl)aminomethane 50; MgCl₂ 1; NaCl 120; KCl 5; pH 7.4). The homogenate was centrifuged for 5 minutes at 1000 g, the supernatant was saved and the pellet re-extracted. The pooled supernatants were centrifuged for 20 minutes at 12000 g, washed, and resuspended in HB. Membranes (30-80 μ g) were incubated with 5 nM [¹²⁵I]- α -BTX, 1 mg/mL BSA (bovine serum albumin), test drug, and either 2 mM CaCl₂ or 0.5 mM EGTA [ethylene glycol-bis(β -aminoethyl) ether] for 2 hours at 21 °C, and then filtered and washed 4 times over Whatman glass fibre filters (thickness C) using a Brandel cell harvester. Pretreating the filters for 3 hours with 1% (BSA/0.01% PEI (polyethyleneimine) in water was critical for low filter blanks (0.07% of total counts per minute). Nonspecific binding was described by 100 μ M (-)-nicotine, and specific binding was typically 75%.

20

Test B - Assay for affinity to the $\alpha 4$ nAChR subtype

[³H]-(-)-Nicotine binding.

Using a procedure modified from Martino-Barrows and Kellar, *Mol. Pharm.*, **31**,169-174, (1987), the contents of which are hereby incorporated herein by reference, rat brain (cortex and hippocampus) was homogenized as in the [¹²⁵I]- α -BTX binding assay, centrifuged for 20 minutes at 12000 g, washed twice, and then resuspended in HB containing 100 μ M diisopropyl fluorophosphate. After 20 minutes at 4 °C, membranes (approximately 0.5 mg) were incubated with 3 nM [³H]-(-)-nicotine, test drug, 1 μ M atropine, and either 2 mM

30

CaCl₂ or 0.5 mM EGTA for 1 hour at 4 °C, and then filtered over Whatman glass fibre filters (thickness B) (pretreated for 1 hour with 0.5% PEI) using a Brandel cell harvester. Nonspecific binding was described by 100 µM carbachol, and specific binding was typically 84%.

5

Binding data analysis for Tests A and B

IC₅₀ values and pseudo Hill coefficients (n_H) were calculated using the non-linear curve fitting program ALLFIT [A. DeLean, P.J. Munson and D. Rodbard, *Am. J. Physiol.*, **235**, E97-E102 (1977)]. Saturation curves were fitted to a one site model, using the non-linear regression program ENZFITTER [R.J. Leatherbarrow (1987)], yielding K_D values of 1.67 and 1.70 nM for the [¹²⁵I]-α-BTX and [³H]-(-)-nicotine ligands respectively. K_i values were estimated using the general Cheng-Prusoff equation:

$$K_i = [IC_{50}] / ((2 + ([ligand]/[K_D])^n)^{1/n} - 1)$$

15 where a value of n=1 was used whenever n_H<1.5 and a value of n=2 was used when n_H≥1.5. Samples were assayed in triplicate and reproducibility was typically ± 5%. K_i values were determined using 6 or more drug concentrations. The compounds of the invention are compounds with binding affinities (K_i) of less than 1000 nM in either Test A or Test B, indicating that they are expected to have useful therapeutic activity.

20

When compared with other compounds, the compounds of the invention have the advantage that they may be less toxic, be more efficacious, be longer acting, have a broader range of activity, be more potent, be more selective for the α7 nAChR subtype, produce fewer side effects, are more easily absorbed or have other useful pharmacological properties.

25

Experimental part

The following Examples illustrate the preparation of compounds of the present invention but in no way limit the scope of the invention.

30

General Experimental Procedures

Commercial reagents were used without further purification. NMR data are reported in parts per million (δ), and are referenced to the chemical shift of tetramethylsilane or the deuterium lock from the sample solvent, and were obtained on either a Bruker 250 MHz or Bruker 500 MHz instrument. Chromatography (silica gel filtration) utilized 230-400 mesh silica gel. Room temperature refers to 20-25°C.

Example 1

General Synthesis of N-Arylcarbamic acid esters, N-Heteroarylcarbamic acid esters, N-Arylthiocarbamic acid esters and N-Heteroarylthiocarbamic acid esters

A mixture of the azabicycloalkyl alcohol (formula VI, 2.00 mmol), the appropriate isocyanate or isothiocyanate (formula VII, 2.00 mmol), triethylamine (20 mol%), and acetonitrile (10 mL) was heated at reflux under nitrogen for 2 to 8 hours, unless otherwise noted. Then, absolute methanol (0.10 mL, 2.5 mmol) was added, and reflux was continued for 1 hour. The resulting reaction solution was cooled to room temperature, and any precipitated solid was isolated via filtration. If the solid was not the pure carbamic acid ester, additional purification could be achieved by recrystallization or column chromatography using silica gel (approximately 50 g) and elution with 9:1:0.1 methylene chloride/methanol/ammonium hydroxide to afford the pure carbamic acid ester.

Following this procedure the following compounds were prepared:

A. N-(4-Bromophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester

3-Quinuclidinol and 4-bromophenyl isocyanate were used. Filtration of the precipitated solid from the cooled reaction mixture afforded the title compound (60%) as a white solid: mp 217.5-219.5 °C; FAB LRMS m/z (relative intensity, %) 328 (16), 327 ($[MH^+$ with Br^{81}], 100), 326 (16), 325 ($[MH^+$ with Br^{79}], 100).

B. N-(4-Methylphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester

3-Quinuclidinol and 4-tolyl isocyanate were used. Filtration of the precipitated solid from
5 the cooled reaction mixture afforded the title compound (93%) as a white solid:
mp 186.0-187.5 °C; FAB LRMS m/z (relative intensity, %) 262 (21), 261 ($[MH]^+$, 100).

C. N-(3,4-Dichlorophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester

10 3-Quinuclidinol and 3,4-dichlorophenyl isocyanate were used. Filtration of the precipitated
solid from the cooled reaction mixture afforded the title compound (60%) as a white solid:
mp 181.0-184.0 °C; FAB LRMS m/z (relative intensity, %) 319 ($[MH]^+$ with two Cl^{37} , 13),
318 (11), 317 ($[MH]^+$ with one Cl^{37} , 71), 316 (18), 315 ($[MH]^+$ with two Cl^{35} , 100).

15 D. N-(4-Methoxyphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester

3-Quinuclidinol and 4-methoxyphenyl isocyanate were used. The solid which precipitated
from the reaction mixture was recrystallized from ethyl acetate to afford the title compound
(43%) as a white solid: mp 159.5-160.5 °C; FAB LRMS m/z (relative intensity, %) 277
20 (MH^+ , 16), 110 (100).

E. N-(2-Fluorophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester

3-Quinuclidinol and 2-fluorophenyl isocyanate were used. The reaction solution was
25 evaporated under reduced pressure, and the residual solid was recrystallized from ethyl
acetate to afford the title compound (79%) as a white solid: mp 124.0-126.0 °C; FAB
LRMS m/z (relative intensity, %) 265 (MH^+ , 22), 110 (100).

F. N-(3-Methoxyphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester

3-Quinuclidinol and 3-methoxyphenyl isocyanate were used. The reaction solution was evaporated under reduced pressure, and the residual solid was recrystallized from ethyl acetate to afford the title compound (60%) as a white solid: mp 130.5-132.0 °C; FAB LRMS m/z (relative intensity, %) 278 (18), 277 (MH^+ , 100).

G. N-Phenylthiocarbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester

3-Quinuclidinol and phenyl isothiocyanate were used. The reaction solution was heated at reflux under nitrogen for 6 days. The reaction solution was chromatographed using silica gel and elution with 10% methanol in methylene chloride followed by a solution of methylene chloride/methanol/ammonium hydroxide (9:1:0.1) to afford a white foam. This foam was dissolved in ethyl acetate/ether (1:9, 10 mL/g of foam), and the resulting cloudy solution was filtered through diatomaceous earth. The resultant filtrate was evaporated under reduced pressure, and the residual foam was crystallized from ethyl acetate/hexanes (1:3) to afford the title compound (29%) as a white solid: mp 132.0-133.0 °C; FAB LRMS m/z (relative intensity, %) 263 (MH^+ , 14), 110 (100).

Example 2

General Synthesis of N-Arylcarbamic acid esters, N-Heteroarylcarbamic acid esters, N-Arylthiocarbamic acid esters and N-Heteroarylthiocarbamic acid esters

To a stirred solution of the appropriate aniline (formula XI, 10.00 mmol) and triethylamine (20 mol%) in anhydrous acetonitrile (50 mL) was added carbonyldiimidazole (1.622 g, 10.00 mmol), and the resulting reaction mixture was stirred at room temperature under nitrogen overnight (16 hours). Then, an alcohol of formula VI (10.00 mmol) was added, and the resulting reaction mixture was heated at reflux under nitrogen for 48 hours. The resulting reaction mixture was evaporated under reduced pressure, and the residue was partitioned between ethyl acetate (150 mL) and saturated aqueous sodium carbonate

(150 mL). The aqueous layer was removed, and the ethyl acetate layer was washed with a saturated aqueous sodium carbonate solution (4 x 100 mL). The ethyl acetate layer was dried (MgSO₄), and evaporated under reduced pressure. The residue was chromatographed using 5 to 20% methanol saturated with ammonia in chloroform to afford the title compound. If necessary, recrystallization can provide more pure title compound.

Following this procedure the following compounds were prepared:

A. N-(4-Cyanophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester

3-Quinuclidinol and 4-aminobenzonitrile were used. Chromatography afforded a residue which was triturated in ethyl acetate to afford the title compound (11%) as a white solid: mp 180.0-182.0 °C; FAB LRMS ^{m/z} (relative intensity, %) 273 (17), 272 (MH⁺, 100), 110 (52).

B. N-(2-Pyridyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester

3-Quinuclidinol and 2-aminopyridine were used. The title compound was isolated as a white solid (8%): mp 166-167 °C; FAB LRMS ^{m/z} 248 (MH⁺).

Example 3

General Synthesis of N-Arylcarbamic acid 1-azabicyclo[2.2.1]heptan-3-yl esters and N-Arylcarbamic acid 1-azabicyclo[2.2.2]octan-3-yl esters

To an ice cold suspension of the appropriate azabicycloalkyl alcohol (formula VI, 13.3 mmol) in tetrahydrofuran (15 mL) was dropwise added over 30 minutes borane-tetrahydrofuran complex (1.0 M in THF, 13.3 mL, 13.3 mmol). The resulting solution was warmed up to room temperature for 1 hour. A few drops of water were added followed by brine solution (30 mL) and ethyl acetate (30 mL). The organic layer was separated, the aqueous layer extracted with ethyl acetate (30 mL), and the combined extracts were dried

(MgSO₄) and evaporated under reduced pressure to give a borane complex of the appropriate azabicycloalkyl alcohol. A solution of the borane complex (2.48 mmol), an aryl isocyanate (formula VII, 3.0 mmol), and triethylamine (0.1 mL) in anhydrous tetrahydrofuran (5 mL) was stirred under nitrogen at room temperature for 24 hours and then evaporated under reduced pressure. The residue was treated with acetone (5 mL) and 2.5 N HCl (3 mL) and stirred at room temperature overnight. The mixture was then evaporated under reduced pressure, and the resulting residue was further purified as required.

Following this procedure the following compounds were prepared:

A. N-Phenylcarbamic acid 1-azabicyclo[2.2.1]heptan-3-yl ester

1-Azabicyclo[2.2.1]heptan-3-endo-ol [*Helv. Chim. Acta*, 75, 507 (1992)] and phenyl isocyanate were used. The residual solid resulting from the above described procedure was recrystallized twice from isopropanol to afford the title compound (56%) as a white crystalline solid: FAB LRMS ^{m/z} (relative intensity, %) 233 ([MH⁺], 100). Anal. calcd. for C₁₃H₁₇N₂O₂Cl: C, 58.10; H, 6.37; N, 10.42. Found C, 58.11; H, 6.40; N, 10.42%.

B. N-Phenylcarbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester

1-Azabicyclo[2.2.2]octan-3-ol and phenyl isocyanate were used. The residual solid resulting from the above described procedure was purified via column chromatography eluting with a 1:10 ratio of methanol:chloroform to afford the title compound (86%) as a white solid: NMR (CDCl₃) δ 7.60-7.0 (m, 5H, Ph), 4.81 (m, 1H, CH-OCO), 3.27 (m, 1H, one of NCH₂C-O), 2.9 (m, 5H, N(CH₂)₂ and one of NCH₂C-O), 2.1 (m, 1H, methine at C₄), 2.05-1.30 (m, 4H, CH₂ at C₅ and C₈); FAB LRMS ^{m/z} (relative intensity, %) 247 ([MH⁺], 100).

C. N-(1-Naphthyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester

1-Naphthylisocyanate and 3-quinuclidinol were used. The title compound was isolated as a white solid (34%): mp 186-188 °C; FAB LRMS m/z 297 (MH^+).

5

Example 4

N-Phenylcarbamic acid (3R)-1-azabicyclo[2.2.2]octan-3-yl ester

A solution of (3R)-(-)-quinuclidin-3-ol (0.30 g, 2.36 mmol) [M. Langlois, C. Meyer, and J. L. Soulier, *Synth. Comm.*, **23**, 1895-1911 (1992)], triethylamine (0.07 mL, 20 mol%) and phenyl isocyanate (0.28 mL, 2.58 mmol, 1.1 equivalents) in anhydrous acetonitrile (5 mL) was heated at reflux under nitrogen for 46 hours. Water (25 mL) was added, and the resulting aqueous mixture was extracted with ethyl acetate (2 x 25 mL). The resulting extracts were combined, dried ($MgSO_4$), and evaporated under reduced pressure. The resulting foam was crystallized using ethyl acetate/hexanes (2:1) to afford a white solid (0.42 g). This white solid was placed in 1N HCl (20 mL), and the resulting aqueous mixture was extracted with ethyl acetate (2 x 25 mL). These organic extracts were discarded. The aqueous solution was made basic (pH > 13) with solid Na_2CO_3 and aqueous 10% KOH. The resulting aqueous solution was extracted with ethyl acetate (2 x 25 mL), and these extracts were combined, dried ($MgSO_4$), and evaporated under reduced pressure. The resulting solid was triturated in ether/hexanes (3:1) to afford the title compound (0.100 g, 17%) as a white, crystalline solid: mp 131.0-132.0 °C; FAB LRMS m/z (relative intensity, %) 247 (MH^+ , 41), 110 (100); $[\alpha]^{22}_D = +7.5^\circ$ (c=0.9, MeOH).

25 Example 5

N-Phenylcarbamic acid (3S)-1-azabicyclo[2.2.2]octan-3-yl ester

A solution of (3S)-(+)-quinuclidin-3-ol (0.50 g, 3.93 mmol) [M. Langlois, C. Meyer, and J. L. Soulier, *Synth. Comm.*, **23**, 1895-1911 (1992)], phenyl isocyanate (0.47 mL, 4.32 mmol, 1.1 equivalents), and dibutyltin dilaurate (0.013 mL, 0.08 mmol) in anhydrous toluene

30

(20 mL) was heated at reflux under nitrogen for 1 hour. The resulting reaction mixture was evaporated under reduced pressure, and the resulting solid was placed in 1N HCl (25 mL). The resulting aqueous mixture was extracted with ethyl acetate (2 x 25 mL), basified to pH 10 with Na₂CO₃, and extracted with chloroform (3 x 50 mL). The chloroform extracts were combined, dried (MgSO₄), and evaporated under reduced pressure. The resulting solid was recrystallized using toluene (5 mL) to afford the title compound (0.875 g, 90%) as a white solid: mp 129.0-130.0 °C; FAB LRMS ^m/z (relative intensity, %) 247 (MH⁺, 39), 110 (100); [α]_D²² = -7.5° (c=1.0, MeOH).

10 Example 6

N-(4-Pyridyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester

3-Quinuclidinol and 4-(2,6-dichloropyridyl)isocyanate were used to synthesise N-[4-(2,6-dichloropyridyl)]carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester following the method described in Example 3. A solution of N-[4-(2,6-dichloropyridyl)]carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester (0.5 g, 1.58 mmol), palladium chloride (0.3 g) and potassium acetate (0.32 g) in methanol (10 mL) was shaken under a hydrogen atmosphere (3 atm). The reaction mixture was filtered, and the filtrate was evaporated under reduced pressure. The residue was partitioned between chloroform and saturated sodium carbonate and separated. The aqueous layer was further extracted with chloroform. The chloroform extracts were combined, dried (MgSO₄) and evaporated to give a solid. This solid was triturated in ether to afford the title compound (69%) as a solid: mp 149-151 °C; FAB LRMS ^m/z 248 (MH⁺).

Example 7

25 General Method for Preparing N-Arylcarbamic acid esters and N-Heteroarylcarbamic acid esters

To a stirred solution of 3-quinuclidinol (10 mmol) in anhydrous chloroform (40 mL) and at 0 °C was added 1.93 M phosgene in toluene (5.2 mL, 10 mmol) under nitrogen, and the resulting mixture was stirred at 0 °C for 1 hour to give a very fine suspension. The appropriate arylamine or heteroarylamine (10 mmol) was then added, followed by

triethylamine (11 mmol). The cooling bath was removed 30 minutes later and the resulting reaction mixture was stirred at room temperature overnight. Chloroform (40 mL) was added to the reaction mixture followed by saturated aqueous sodium bicarbonate until the mixture was basic. The chloroform layer was separated. The aqueous layer was further
5 extracted with chloroform (30 mL). The organic layers were combined, dried (MgSO_4) and evaporated under reduced pressure. The residue was purified by column chromatography eluting with 3 to 5% methanol saturated with ammonia in chloroform to give the pure carbamic acid ester.

10 Following this procedure the following compounds were synthesized:

A. N-(m-Biphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester

3-Quinuclidinol and m-aminobiphenyl were used to give the title compound (26%) as white crystals: mp 203-204.5 °C; FAB LRMS m/z 323 (MH^+).


15

B. N-(3-Quinoliny)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester

3-Quinuclidinol and 3-aminoquinoline were used to give the title compound (46%) as a solid: mp 135-137 °C; FAB LRMS m/z 298 (MH^+).

Claims


1. A compound of formula



5

wherein:

A is



10

X is O or S;

Y is O or S;

G and D are independently nitrogen or carbon with the proviso that no more than one of G,

15 D, or E is nitrogen;

E is N or C-R₄;

R₁ is hydrogen or methyl;

R₂ is hydrogen or fluoro;

R₃ is hydrogen, halogen, C₁ to C₃ alkyl, -OR₅, -CN, -CONH₂, -CO₂R₅, -NR₅R₆ or phenyl

20 optionally substituted with one to three of the following substituents: halogen, C₁ to C₃

alkyl, -NO₂, -CN, or -OCH₃;

R₄ is hydrogen, halogen, C₁ to C₃ alkyl, -OR₅, -CN, -CONH₂, -CO₂R₅, -NR₅R₆ or phenyl optionally substituted with one to three of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃;

or R₂ and R₃ or R₃ and R₄ may together represent a fused phenyl ring optionally substituted with one or two of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃;

R₅ and R₆ are independently hydrogen or C₁ to C₃ alkyl;

or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

2. A compound of formula I, according to claim 1, wherein A is either formula II or formula IV.

3. A compound of formula I, according to claim 1, wherein R₂ is hydrogen.

4. A compound of formula I, according to claim 1, wherein X and Y are oxygen.

5. A compound of formula I, according to claim 1, wherein G, D, and E are carbon.

6. A compound of formula I, according to claim 1, wherein A is either formula II or formula IV, R₂ is hydrogen, X and Y are oxygen, and G, D, and E are carbon.

7. A compound of formula I, according to claim 1, said compound being:

N-phenylcarbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;

N-(4-bromophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;

N-(4-methylphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;

N-(4-methoxyphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;

N-(3,4-dichlorophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;

N-(4-cyanophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;

N-phenylcarbamic acid 1-azabicyclo[2.2.1]heptan-3-yl ester;

N-(3-methoxyphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;

N-phenylthiocarbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(2-pyridyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(1-naphthyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-phenylcarbamic acid (3R)-1-azabicyclo[2.2.2]octan-3-yl ester;
5 N-phenylcarbamic acid (3S)-1-azabicyclo[2.2.2]octan-3-yl ester;
N-(4-pyridyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(m-biphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(3-quinolinyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

10

8. A compound of formula I, according to claim 1, said compound being:
N-(4-bromophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(4-methylphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
N-(3,4-dichlorophenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
15 N-(m-biphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl ester;
or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

9. A pharmaceutical composition including a compound of formula I, as defined in any one of claims 1 to 8, or an enantiomer thereof, or a pharmaceutically acceptable salt thereof,
20 in admixture with an inert pharmaceutically acceptable diluent or carrier.

10. A compound of formula I, according to any one of claims 1 to 8, or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical.

25 11. The use of a compound of formula I, as defined in any one of claims 1 to 8, or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of psychotic disorders or intellectual impairment disorders.

12. The use as claimed in claim 11, wherein the condition or disorder is Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, autism or Attention Deficit Hyperactivity Disorder.

5 13. The use as claimed in claim 11 wherein the condition or disorder is anxiety, schizophrenia, mania or manic depression.

14. The use of a compound of formula I, as defined in any one of claims 1 to 8, or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a
10 medicament for the treatment or prophylaxis of Parkinson's disease, Huntington's disease, Tourette's syndrome, Amyotrophic Lateral Sclerosis or neurodegenerative disorders in which there is dysfunction of the cholinergic system.

15. The use of a compound of formula I, as defined in any one of claims 1 to 8, or an enantiomer thereof, or a pharmaceutically acceptable salt thereof,, in the manufacture of a
15 medicament for the treatment or prophylaxis of jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, pain, and inflammatory bowel diseases.

20 16. A method of treatment or prophylaxis of psychotic disorders or intellectual impairment disorders, which comprises administering a therapeutically effective amount of a compound of formula I, as defined in any one of claims 1 to 8, or an enantiomer thereof, or a pharmaceutically acceptable salt thereof.

25 17. The method claimed in claim 16, wherein the condition or disorder to be treated is Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, autism or Attention Deficit Hyperactivity Disorder.


30 18. The method claimed in claim 16, wherein the condition or disorder to be treated is anxiety, schizophrenia, mania or manic depression.

19. A method of treatment or prophylaxis of Parkinson's disease, Huntington's disease, Tourette's syndrome, Amyotrophic Lateral Sclerosis or neurodegenerative disorders in which there is dysfunction of the cholinergic system, which comprises administering a therapeutically effective amount of a compound of formula I, as defined in any one of claims 1 to 8, or an enantiomer thereof, or a pharmaceutically acceptable salt thereof.

20. A method of treatment or prophylaxis of jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, pain, and inflammatory bowel diseases which comprises administering a therapeutically effective amount of a compound of formula I, as defined in any one of claims 1 to 8, or an enantiomer thereof, or a pharmaceutically acceptable salt thereof.


21. A process for the preparation of a compound of formula I, as defined in any one of claims 1 to 8, or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, which comprises:

a) the condensation of a compound of formula VI, wherein A and X are as defined in claim 1, with an isocyanate or isothiocyanate of the formula VII, wherein Y, G, D, E, R₂ and R₃ are as defined in claim 1, in an inert solvent in the presence of a catalyst, for example, triethylamine or dibutyltin dilaurate:




or

- b) the removal of the borane from the complex of formula IX, wherein A, X, Y, G, D, E, R₂ and R₃ are as defined in claim 1, using acid in an inert solvent:



or


- c) the sequential reaction of a compound of formula XI, wherein G, D, E, R₂ and R₃ are as defined in claim 1, with a carbonyl donating compound of formula XII, wherein Y is as defined in claim 1 and L is a leaving group, for example, chloride or imidazole, followed by reaction of the resulting mixture with a compound of formula VI, wherein A and X are as defined in claim 1, all done in the presence of a basic catalyst in an inert solvent:



and where desired or necessary converting the resultant compound of formula I, or an enantiomer thereof or an acid addition salt thereof, to a pharmaceutically acceptable acid addition salt thereof, or converting the resultant racemic mixture of the compound of formula I to an enantiomer thereof.


5

22. A compound of formula IX



10 wherein:

A is



15 X is O or S;

Y is O or S;

G and D are independently nitrogen or carbon with the proviso that no more than one of G,

D, or E is nitrogen;

E is N or C-R₄;

20 R₁ is hydrogen or methyl;

R₂ is hydrogen or fluoro;

R₃ is hydrogen, halogen, C₁ to C₃ alkyl, -OR₅, -CN, -CONH₂, -CO₂R₅, -NR₅R₆ or phenyl optionally substituted with one to three of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃;

R₄ is hydrogen, halogen, C₁ to C₃ alkyl, -OR₅, -CN, -CONH₂, -CO₂R₅, -NR₅R₆ or phenyl optionally substituted with one to three of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃;

or R₂ and R₃ or R₃ and R₄ may together represent a fused phenyl ring optionally substituted with one or two of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃;


R₅ and R₆ are independently hydrogen or C₁ to C₃ alkyl; or an enantiomer thereof.

23. A compound of formula VIII

BH₃-A-XH VIII

wherein

A is



X is O or S.

24. Use of a compound according to claim 23 as starting material in condensation reactions.

25. Use of a compound according to claim 23 as starting material in a synthesis of a ligand for nicotinic acetylcholine receptors.

AMENDED CLAIMS

[received by the International Bureau on 14 July 1997 (14.07.97);
original claims 23-25 cancelled; remaining claims unchanged (1 page)]

R₃ is hydrogen, halogen, C₁ to C₃ alkyl, -OR₅, -CN, -CONH₂, -CO₂R₅, -NR₅R₆ or phenyl optionally substituted with one to three of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃;

R₄ is hydrogen, halogen, C₁ to C₃ alkyl, -OR₅, -CN, -CONH₂, -CO₂R₅, -NR₅R₆ or phenyl
5 optionally substituted with one to three of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃;

or R₂ and R₃ or R₃ and R₄ may together represent a fused phenyl ring optionally substituted with one or two of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃;

10 R₅ and R₆ are independently hydrogen or C₁ to C₃ alkyl;
or an enantiomer thereof.

AMENDED SHEET (ARTICLE 19)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 97/00294

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07D 453/02, C07D 453/06, C07D 487/08, A61K 31/445, C07F 5/02
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS-ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Acta Pharm. Suecica, Volume 7, 1970, J. Lars G. Nilsson et al, "Studies on carbanilic acid esters of cyclic amino alcohols" page 239 - page 246 --	1-15,21-22
A	Acta Pharm. Suecica, Volume 4, 1967, Richard Dahlbom et al, "3,4, 5-Trimethoxyphenylcarbamic acid esters of some cyclic amino alcohols" page 211 - page 216 --	1-15,21-22
A	Chemical Abstracts, Volume 124, No 5, 29 January 1996 (29.01.96), (Columbus, Ohio, USA), page 1213, THE ABSTRACT No 55799b, WO, 9521168 A1,, (Daniel Paul et al) 10 August 1995 (10.08.95) --	1-15,21-22

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

3 June 1997

05-06-1997

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Göran Karlsson
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 97/00294

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5468875 A (ANNMARIE L. SABB ET AL), 21 November 1995 (21.11.95) --	1-15,21-22
A	EP 0497303 A2 (KYORIN PHARMACEUTICAL CO., LTD.), 5 August 1992 (05.08.92) --	1-15,21-22
X	Chemical Abstracts, Volume 108, No 17, 25 April 1988 (25.04.88), (Columbus, Ohio, USA), Stotter, Philip L. et al, "Quinuclidine-boranes as intermediates in formation and isolation of functionalized quinuclidine systems", page 778, THE ABSTRACT No 150772r, Heterocycles 1987, 25 (1), 251-258 --	23-25
X	DE 3839385 A1 (BOEHRINGER INGELHEIM KG), 23 May 1990 (23.05.90) -- -----	23-25

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 97/00284

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 16-20
because they relate to subject matter not required to be searched by this Authority, namely:
A method for treatment of the human or animal body by therapy, see rule 39.1
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Invention 1. Claims 1-15 and 21 directed to a pharmaceutically active compound I and claim 22 (intermediate IX)

Invention 2. Claim 23-25 directed to compound VIII and the use thereof.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☒

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

20/05/97

International application No.

PCT/SE 97/00294

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9521168 A1	10/08/95	AU 1603595 A	21/08/95
		US 5530018 A	25/06/96

US 5468875 A	21/11/95	NONE	

EP 0497303 A2	05/08/92	AU 643590 B	18/11/93
		AU 1064992 A	06/08/92
		CN 1064075 A	02/09/92
		JP 5058999 A	09/03/93
		KR 9609429 B	19/07/96
		CA 2060393 A	01/08/92
		US 5300515 A	05/04/94

DE 3839385 A1	23/05/90	AU 628884 B	24/09/92
		AU 4540389 A	31/05/90
		CA 2003422 A	22/05/90
		DE 8817121 U	04/02/93
		DK 170167 B	06/06/95
		EP 0370415 A,B	30/05/90
		SE 0370415 T3	
		ES 2054988 T	16/08/94
		FI 91637 B,C	15/04/94
		IE 62328 B	25/01/95
		IL 92377 A	24/01/95
		JP 2243688 A	27/09/90
		JP 6086449 B	02/11/94
		PT 92368 B	18/07/95
		US 5286864 A	15/02/94
US 5451587 A	19/09/95		
US 5508405 A	16/04/96		
